PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer

Emmanuel O. Johnson, Kuei Hua Chang, Yolanda de Pablo, Soumitra Ghosh, Rutika Mehta, Sunil Badve, Kavita Shah

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Aurora A kinase is overexpressed in the majority of breast carcinomas. A chemical genetic approach was used to identify the malignant targets of Aurora A, which revealed pleckstrin-homology-like domain protein PHLDA1 as an Aurora A substrate. PHLDA1 downregulation is a powerful prognostic predictor for breast carcinoma, which was confirmed in our study. We further show that downregulation of PHLDA1 is associated with estrogen receptor (ER) expression in breast carcinoma. Aurora A directly phosphorylates PHLDA1 leading to its degradation. PHLDA1 also negatively regulates Aurora A, thereby triggering a feedback loop. We demonstrate the underlying mechanisms by which PHLDA1 upregulation strongly antagonizes Aurora-A-mediated oncogenic pathways, thereby revealing PHLDA1 degradation as a key mechanism by which Aurora A promotes breast malignancy. Thus, not surprisingly, PHLDA1 upregulation acts synergistically with Aurora A inhibition in promoting cell death. PHLDA1 overexpression might therefore be an alternative method to modulate Aurora A deregulation in breast carcinoma. Finally, this study led to the discovery of a mutation in the Aurora A active site that renders it amenable to the chemical genetic approach. Similar mutations are required for Aurora B, suggesting that this modified approach can be extended to other kinases that have hitherto not been amenable to this methodology.

Original languageEnglish
Pages (from-to)2711-2722
Number of pages12
JournalJournal of Cell Science
Volume124
Issue number16
DOIs
StatePublished - Aug 15 2011

Fingerprint

Aurora Kinase A
Breast Neoplasms
Up-Regulation
Down-Regulation
Mutation
Estrogen Receptors
Catalytic Domain
Breast
Cell Death
Phosphotransferases
Neoplasms
Proteins

Keywords

  • Analog-sensitive kinase
  • Aurora kinase
  • Cancer
  • Chemical biology
  • PHLDA1

ASJC Scopus subject areas

  • Cell Biology

Cite this

Johnson, E. O., Chang, K. H., de Pablo, Y., Ghosh, S., Mehta, R., Badve, S., & Shah, K. (2011). PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer. Journal of Cell Science, 124(16), 2711-2722. https://doi.org/10.1242/jcs.084970

PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer. / Johnson, Emmanuel O.; Chang, Kuei Hua; de Pablo, Yolanda; Ghosh, Soumitra; Mehta, Rutika; Badve, Sunil; Shah, Kavita.

In: Journal of Cell Science, Vol. 124, No. 16, 15.08.2011, p. 2711-2722.

Research output: Contribution to journalArticle

Johnson, EO, Chang, KH, de Pablo, Y, Ghosh, S, Mehta, R, Badve, S & Shah, K 2011, 'PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer', Journal of Cell Science, vol. 124, no. 16, pp. 2711-2722. https://doi.org/10.1242/jcs.084970
Johnson, Emmanuel O. ; Chang, Kuei Hua ; de Pablo, Yolanda ; Ghosh, Soumitra ; Mehta, Rutika ; Badve, Sunil ; Shah, Kavita. / PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer. In: Journal of Cell Science. 2011 ; Vol. 124, No. 16. pp. 2711-2722.
@article{3764096892df4008a7eb51b28bed3d96,
title = "PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer",
abstract = "Aurora A kinase is overexpressed in the majority of breast carcinomas. A chemical genetic approach was used to identify the malignant targets of Aurora A, which revealed pleckstrin-homology-like domain protein PHLDA1 as an Aurora A substrate. PHLDA1 downregulation is a powerful prognostic predictor for breast carcinoma, which was confirmed in our study. We further show that downregulation of PHLDA1 is associated with estrogen receptor (ER) expression in breast carcinoma. Aurora A directly phosphorylates PHLDA1 leading to its degradation. PHLDA1 also negatively regulates Aurora A, thereby triggering a feedback loop. We demonstrate the underlying mechanisms by which PHLDA1 upregulation strongly antagonizes Aurora-A-mediated oncogenic pathways, thereby revealing PHLDA1 degradation as a key mechanism by which Aurora A promotes breast malignancy. Thus, not surprisingly, PHLDA1 upregulation acts synergistically with Aurora A inhibition in promoting cell death. PHLDA1 overexpression might therefore be an alternative method to modulate Aurora A deregulation in breast carcinoma. Finally, this study led to the discovery of a mutation in the Aurora A active site that renders it amenable to the chemical genetic approach. Similar mutations are required for Aurora B, suggesting that this modified approach can be extended to other kinases that have hitherto not been amenable to this methodology.",
keywords = "Analog-sensitive kinase, Aurora kinase, Cancer, Chemical biology, PHLDA1",
author = "Johnson, {Emmanuel O.} and Chang, {Kuei Hua} and {de Pablo}, Yolanda and Soumitra Ghosh and Rutika Mehta and Sunil Badve and Kavita Shah",
year = "2011",
month = "8",
day = "15",
doi = "10.1242/jcs.084970",
language = "English",
volume = "124",
pages = "2711--2722",
journal = "Journal of Cell Science",
issn = "0021-9533",
publisher = "Company of Biologists Ltd",
number = "16",

}

TY - JOUR

T1 - PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer

AU - Johnson, Emmanuel O.

AU - Chang, Kuei Hua

AU - de Pablo, Yolanda

AU - Ghosh, Soumitra

AU - Mehta, Rutika

AU - Badve, Sunil

AU - Shah, Kavita

PY - 2011/8/15

Y1 - 2011/8/15

N2 - Aurora A kinase is overexpressed in the majority of breast carcinomas. A chemical genetic approach was used to identify the malignant targets of Aurora A, which revealed pleckstrin-homology-like domain protein PHLDA1 as an Aurora A substrate. PHLDA1 downregulation is a powerful prognostic predictor for breast carcinoma, which was confirmed in our study. We further show that downregulation of PHLDA1 is associated with estrogen receptor (ER) expression in breast carcinoma. Aurora A directly phosphorylates PHLDA1 leading to its degradation. PHLDA1 also negatively regulates Aurora A, thereby triggering a feedback loop. We demonstrate the underlying mechanisms by which PHLDA1 upregulation strongly antagonizes Aurora-A-mediated oncogenic pathways, thereby revealing PHLDA1 degradation as a key mechanism by which Aurora A promotes breast malignancy. Thus, not surprisingly, PHLDA1 upregulation acts synergistically with Aurora A inhibition in promoting cell death. PHLDA1 overexpression might therefore be an alternative method to modulate Aurora A deregulation in breast carcinoma. Finally, this study led to the discovery of a mutation in the Aurora A active site that renders it amenable to the chemical genetic approach. Similar mutations are required for Aurora B, suggesting that this modified approach can be extended to other kinases that have hitherto not been amenable to this methodology.

AB - Aurora A kinase is overexpressed in the majority of breast carcinomas. A chemical genetic approach was used to identify the malignant targets of Aurora A, which revealed pleckstrin-homology-like domain protein PHLDA1 as an Aurora A substrate. PHLDA1 downregulation is a powerful prognostic predictor for breast carcinoma, which was confirmed in our study. We further show that downregulation of PHLDA1 is associated with estrogen receptor (ER) expression in breast carcinoma. Aurora A directly phosphorylates PHLDA1 leading to its degradation. PHLDA1 also negatively regulates Aurora A, thereby triggering a feedback loop. We demonstrate the underlying mechanisms by which PHLDA1 upregulation strongly antagonizes Aurora-A-mediated oncogenic pathways, thereby revealing PHLDA1 degradation as a key mechanism by which Aurora A promotes breast malignancy. Thus, not surprisingly, PHLDA1 upregulation acts synergistically with Aurora A inhibition in promoting cell death. PHLDA1 overexpression might therefore be an alternative method to modulate Aurora A deregulation in breast carcinoma. Finally, this study led to the discovery of a mutation in the Aurora A active site that renders it amenable to the chemical genetic approach. Similar mutations are required for Aurora B, suggesting that this modified approach can be extended to other kinases that have hitherto not been amenable to this methodology.

KW - Analog-sensitive kinase

KW - Aurora kinase

KW - Cancer

KW - Chemical biology

KW - PHLDA1

UR - http://www.scopus.com/inward/record.url?scp=79961152605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961152605&partnerID=8YFLogxK

U2 - 10.1242/jcs.084970

DO - 10.1242/jcs.084970

M3 - Article

C2 - 21807936

AN - SCOPUS:79961152605

VL - 124

SP - 2711

EP - 2722

JO - Journal of Cell Science

JF - Journal of Cell Science

SN - 0021-9533

IS - 16

ER -